A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

被引：5

作者：

Ong, Faustine ^{[1
]}

Short, Nicholas ^{[2
]}

Daver, Naval ^{[2
]}

Kadia, Tapan M. ^{[2
]}

DiNardo, Courtney D. ^{[2
]}

Yilmaz, Musa ^{[2
]}

Alvarado, Yesid ^{[2
]}

Vaughan, Kenneth ^{[2
]}

Pierce, Sherry A. ^{[2
]}

Kantarjian, Hagop ^{[3
]}

Garcia-Manero, Guillermo ^{[2
]}

Ravandi, Farhad ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

615

引用

页码：9029 / 9031

页数：3

共 50 条

[1] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Briski, Robert
Short, Nicholas J.
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Valero, Yesid Alvarado
Vaughan, Kenneth
Pierce, Sherry
Montalbano, Kathryn
Mullin, Jillian
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2023, 142
[2] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
Wang, Eunice S.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
[4] Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3Mutated Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark R.
McCloskey, James
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Naqvi, Kiran
Dail, Monique
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
BLOOD, 2021, 138
[5] Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Yilmaz, Musa
Kantarjian, Hagop
Short, Nicholas J.
Reville, Patrick
Konopleva, Marina
Kadia, Tapan
DiNardo, Courtney
Borthakur, Gautam
Pemmaraju, Naveen
Maiti, Abhishek
Jabbour, Elias
Jain, Nitin
Issa, Ghayas
Takahashi, Koichi
Sasaki, Koji
Ohanian, Maro
Pierce, Sherry
Tang, Guillin
Loghavi, Sanam
Patel, Keyur
Wang, Sa A.
Garcia-Manero, Guillermo
Andreeff, Michael
Ravandi, Farhad
Daver, Naval
BLOOD CANCER JOURNAL, 2022, 12 (05)
[6] Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz
Hagop Kantarjian
Nicholas J. Short
Patrick Reville
Marina Konopleva
Tapan Kadia
Courtney DiNardo
Gautam Borthakur
Naveen Pemmaraju
Abhishek Maiti
Elias Jabbour
Nitin Jain
Ghayas Issa
Koichi Takahashi
Koji Sasaki
Maro Ohanian
Sherry Pierce
Guillin Tang
Sanam Loghavi
Keyur Patel
Sa A. Wang
Guillermo Garcia-Manero
Michael Andreeff
Farhad Ravandi
Naval Daver
Blood Cancer Journal, 12
[7] Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
Numan, Yazan
Rahman, Zaid Abdel
Grenet, Justin
Boisclair, Stephanie
Bewersdorf, Jan Philipp
Barth, Dylan
Zeidan, Amer M.
Yilmaz, Musa
Dinner, Shira
Deutsch, Yehuda E.
Frankfurt, Olga
Litzow, Mark
Al-Kali, Aref
Foran, James M.
Sproat, Lisa Z.
Jovanovic, Borko
Daver, Naval
Perl, Alexander E.
Altman, Jessica K.
BLOOD, 2020, 136
[8] Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
Abuasab, Tareq
Kantarjian, Hagop
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Yilmaz, Musa
Pemmaraju, Naveen
Chien, Kelly S.
Mohamed, Shehab Fareed
Daver, Naval
Kornblau, Steven M.
Burger, Jan A.
Jain, Nitin
Islam, Rubiul
DiNardo, Courtney D.
Borthakur, Gautam
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2021, 138
[9] Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Numan, Yazan
Abdel Rahman, Zaid
Grenet, Justin
Boisclair, Stephanie
Bewersdorf, Jan Philipp
Collins, Cailin
Barth, Dylan
Fraga, Martina
Bixby, Dale L.
Zeidan, Amer M.
Yilmaz, Musa
Desai, Pankil
Mannis, Gabriel
Deutsch, Yehuda E.
Abaza, Yasmin
Dinner, Shira
Frankfurt, Olga
Litzow, Mark
Al-Kali, Aref
Foran, James M.
Sproat, Lisa Z.
Jovanovic, Borko
Daver, Naval
Perl, Alexander E.
Altman, Jessica K.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : 322 - 328
[10] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Ravandi, Farhad
Garcia-Manero, Guillermo
Jabbour, Elias
DiNardo, Courtney D.
Kadia, Tapan M.
Ning, Jing
Nogueras-Gonzalez, Graciela
Pierce, Sherry
Gombos, Dan
Komblau, Steven
Konopleva, Marina
Kelly, Mary
Borthakur, Gautam
Zhang, Weiguo
Cortes, Jorge
Kantarjian, Hagop
Andreeffl, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8

← 1 2 3 4 5 →